Nothing Special   »   [go: up one dir, main page]

EE05214B1 - Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon - Google Patents

Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon

Info

Publication number
EE05214B1
EE05214B1 EEP200000614A EEP200000614A EE05214B1 EE 05214 B1 EE05214 B1 EE 05214B1 EE P200000614 A EEP200000614 A EE P200000614A EE P200000614 A EEP200000614 A EE P200000614A EE 05214 B1 EE05214 B1 EE 05214B1
Authority
EE
Estonia
Prior art keywords
ifn
polyol
conjugate
preparation
pharmaceutical composition
Prior art date
Application number
EEP200000614A
Other languages
English (en)
Inventor
El Tayar Nabil
J. Roberts Michael
Harris Milton
Sawlivich Wayne
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of EE200000614A publication Critical patent/EE200000614A/et
Publication of EE05214B1 publication Critical patent/EE05214B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200000614A 1998-04-28 1999-04-28 Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon EE05214B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8333998P 1998-04-28 1998-04-28
PCT/US1999/009161 WO1999055377A2 (en) 1998-04-28 1999-04-28 Polyol-ifn-beta conjugates

Publications (2)

Publication Number Publication Date
EE200000614A EE200000614A (et) 2002-04-15
EE05214B1 true EE05214B1 (et) 2009-10-15

Family

ID=22177687

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000614A EE05214B1 (et) 1998-04-28 1999-04-28 Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon

Country Status (31)

Country Link
US (3) US6638500B1 (et)
EP (2) EP1075281B1 (et)
JP (2) JP4574007B2 (et)
KR (1) KR100622796B1 (et)
CN (2) CN100335503C (et)
AR (1) AR020070A1 (et)
AT (2) ATE365563T1 (et)
AU (1) AU762621B2 (et)
BG (2) BG64694B1 (et)
BR (1) BR9910023A (et)
CA (2) CA2330451A1 (et)
CY (1) CY1108022T1 (et)
CZ (2) CZ298597B6 (et)
DE (2) DE69936409T2 (et)
DK (2) DK1421956T3 (et)
EA (2) EA200300382A1 (et)
EE (1) EE05214B1 (et)
ES (2) ES2285286T3 (et)
HK (2) HK1038194A1 (et)
HU (1) HUP0300548A3 (et)
IL (1) IL139286A (et)
NO (2) NO329749B1 (et)
NZ (1) NZ507456A (et)
PL (2) PL196533B1 (et)
PT (2) PT1075281E (et)
SI (2) SI1421956T1 (et)
SK (2) SK286654B6 (et)
TR (2) TR200101751T2 (et)
TW (2) TWI266800B (et)
UA (2) UA66857C2 (et)
WO (1) WO1999055377A2 (et)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
MXPA01003790A (es) 1998-10-16 2002-09-18 Biogen Inc Proteinas de fusion beta - interferon y sus usos.
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US6342244B1 (en) * 1999-04-23 2002-01-29 Alza Corporation Releasable linkage and compositions containing same
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
TR200101086A3 (et) * 1999-10-15 2001-08-21
JP4593048B2 (ja) * 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
CN1188172C (zh) 2000-01-10 2005-02-09 马克西根控股公司 G－csf偶联物
NZ521257A (en) 2000-02-11 2004-10-29 Maxygen Aps Factor VII or VIIa-like molecules
WO2002060978A1 (fr) 2001-01-30 2002-08-08 Kyowa Hakko Kogyo Co., Ltd. Polyalkylene glycols ramifies
EP1234583A1 (en) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
MXPA03007619A (es) 2001-02-27 2003-12-04 Maxygen Aps Nuevas moleculas similares a interferon beta.
BR0211071A (pt) 2001-07-11 2004-12-21 Maxygen Holdings Ltd Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
NZ534708A (en) 2002-01-18 2007-05-31 Biogen Idec Inc Polyalkylene glycol with moiety for conjugating biologically active compound
TWI334785B (en) 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004060300A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
JP5207590B2 (ja) * 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
ES2386010T3 (es) 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
EP1740608B1 (en) 2004-02-02 2012-02-22 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
EP1586334A1 (en) * 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
CA2566364A1 (en) 2004-05-17 2005-11-24 Ares Trading S.A. Hydrogel interferon formulations
AU2005249232B2 (en) 2004-06-01 2010-08-05 Ares Trading S.A. Method of stabilizing proteins
EA010979B1 (ru) 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
US7851565B2 (en) 2004-12-21 2010-12-14 Nektar Therapeutics Stabilized polymeric thiol reagents
GB2438760A (en) 2004-12-22 2007-12-05 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
BRPI0519170A8 (pt) * 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
KR20080033439A (ko) * 2005-08-04 2008-04-16 넥타르 테라퓨틱스 에이엘, 코포레이션 Ｇ-ｃｓｆ 부분 및 중합체의 컨주게이트
RS57549B1 (sr) 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
EP2444499A3 (en) * 2006-05-02 2012-05-09 Allozyne, Inc. Amino acid substituted molecules
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
CA2649810A1 (en) 2006-05-24 2007-11-29 Laboratoires Serono S.A. Cladribine regimen for treating multiple sclerosis
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
ATE555812T1 (de) * 2007-12-20 2012-05-15 Merck Serono Sa Peg-interferon-beta-formulierungen
CN101939443B (zh) 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
US20100112660A1 (en) * 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110124614A1 (en) * 2008-10-25 2011-05-26 Halina Offner Methods And Compositions For The Treatment of Autoimmune Disorders
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
JP2013532176A (ja) 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
CN103209992A (zh) 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
EP2676675B1 (en) 2011-02-18 2019-04-10 Stemdr Inc. Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP2762489B1 (en) * 2011-10-01 2018-03-28 Glytech, Inc. Glycosylated polypeptide and pharmaceutical composition containing same
EA037979B1 (ru) 2012-02-27 2021-06-18 Амуникс Оперейтинг Инк. Композиции конъюгата xten и способы их получения
RU2597795C2 (ru) 2012-02-29 2016-09-20 Торэй Индастриз, Инк. Ингибитор скопления жидкости в полостях организма
ES2687801T3 (es) 2013-03-29 2018-10-29 Glytech, Inc. Polipéptido presentando cadenas de azúcares sialiladas unidas al mismo
KR101671501B1 (ko) * 2014-07-24 2016-11-03 에이비온 주식회사 페길화된 인터페론-베타 변이체
WO2016013697A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체
DK3183264T3 (da) 2014-08-19 2020-11-02 Biogen Ma Inc Pegyleringsfremgangsmåde
ES2903448T3 (es) 2015-05-01 2022-04-01 Allysta Pharmaceuticals Inc Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares
PL3310816T3 (pl) * 2015-06-19 2020-12-14 Eisai R&D Management Co., Ltd. Immunoglobuliny sprzężone na cys80
CN118064414A (zh) * 2017-04-17 2024-05-24 科罗拉多州立大学董事会法人团体 治疗同型半胱氨酸尿症的酶替代疗法优化
US20220220176A1 (en) 2019-01-28 2022-07-14 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof
US20220118050A1 (en) 2019-01-28 2022-04-21 Toray Industries, Inc. Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5208344A (en) * 1987-07-31 1993-05-04 American Home Products Corporation Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ES2174915T3 (es) 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
US5766581A (en) 1994-03-31 1998-06-16 Amgen Inc. Method for treating mammals with monopegylated proteins that stimulates megakaryocyte growth and differentiation
DE69534318T2 (de) * 1994-05-18 2006-04-20 Nektar Therapeutics, San Carlos Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
KR0176625B1 (ko) 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
EP0921817B1 (en) * 1997-01-29 2001-03-28 PolyMASC Pharmaceuticals plc Pegylation process
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates

Also Published As

Publication number Publication date
BG65046B1 (bg) 2007-01-31
EA003789B1 (ru) 2003-10-30
CN1187094C (zh) 2005-02-02
HK1038194A1 (en) 2002-03-08
US6638500B1 (en) 2003-10-28
AU3767499A (en) 1999-11-16
SI1075281T1 (en) 2005-02-28
NO329749B1 (no) 2010-12-13
AR020070A1 (es) 2002-04-10
ES2224649T3 (es) 2005-03-01
EP1421956A1 (en) 2004-05-26
US7700314B2 (en) 2010-04-20
JP2010184929A (ja) 2010-08-26
CA2565375A1 (en) 1999-11-04
DK1421956T3 (da) 2007-10-01
TR200003161T2 (tr) 2001-01-22
SK286217B6 (sk) 2008-05-06
WO1999055377A3 (en) 1999-12-29
EA200001111A1 (ru) 2001-04-23
SK16222000A3 (sk) 2001-04-09
PL196533B1 (pl) 2008-01-31
BR9910023A (pt) 2000-12-26
NO20005337L (no) 2000-12-28
TR200101751T2 (tr) 2002-05-21
EE200000614A (et) 2002-04-15
DE69936409D1 (de) 2007-08-09
IL139286A0 (en) 2001-11-25
ATE275422T1 (de) 2004-09-15
DE69936409T2 (de) 2008-04-17
HUP0300548A2 (hu) 2003-06-28
PT1075281E (pt) 2004-11-30
NO20005337D0 (no) 2000-10-23
SK286654B6 (sk) 2009-03-05
CA2330451A1 (en) 1999-11-04
WO1999055377A2 (en) 1999-11-04
US7357925B2 (en) 2008-04-15
BG109291A (en) 2006-04-28
TWI266800B (en) 2006-11-21
KR20010071158A (ko) 2001-07-28
UA66857C2 (uk) 2004-06-15
EP1075281A2 (en) 2001-02-14
CY1108022T1 (el) 2013-09-04
UA79430C2 (en) 2007-06-25
HK1076115A1 (en) 2006-01-06
DE69920002D1 (de) 2004-10-14
EP1075281B1 (en) 2004-09-08
ATE365563T1 (de) 2007-07-15
EP1421956B1 (en) 2007-06-27
ES2285286T3 (es) 2007-11-16
SI1421956T1 (sl) 2007-10-31
NO20100324L (no) 2000-12-28
EA005495B1 (ru) 2005-02-24
DK1075281T3 (da) 2005-01-03
TWI232882B (en) 2005-05-21
CZ20003995A3 (en) 2001-06-13
CN1302209A (zh) 2001-07-04
CN100335503C (zh) 2007-09-05
CZ298579B6 (cs) 2007-11-14
US20070141620A1 (en) 2007-06-21
JP2002512983A (ja) 2002-05-08
CZ298597B6 (cs) 2007-11-21
IL139286A (en) 2005-12-18
NO332224B1 (no) 2012-07-30
HUP0300548A3 (en) 2005-07-28
PL344490A1 (en) 2001-11-05
JP4574007B2 (ja) 2010-11-04
WO1999055377A9 (en) 2000-03-02
EA200300382A1 (ru) 2005-02-24
US20040043002A1 (en) 2004-03-04
KR100622796B1 (ko) 2006-09-13
BG64694B1 (bg) 2005-12-30
NZ507456A (en) 2003-10-31
DE69920002T2 (de) 2005-09-22
PL193352B1 (pl) 2007-02-28
PT1421956E (pt) 2007-07-13
CN1637020A (zh) 2005-07-13
BG104871A (en) 2001-07-31
AU762621B2 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
EE05214B1 (et) Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
EE200000596A (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod
EE200100684A (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
EE04275B1 (et) Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE200100033A (et) Enterokattega ravimkoostis ja selle valmistamise meetod
EE200000680A (et) Enterokattega ravimkoostis ja selle valmistamise meetod
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
EE200100252A (et) Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE9800302A (et) Arüülglütsiinamiidi derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline preparaat
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE9800200A (et) Bensoüülguanidiini derivaadid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE200000767A (et) Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
EE04119B1 (et) Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
EE04902B1 (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
EE03691B1 (et) 1,2,3,4-tetrahüdrobensofuro[3,4-c]püridiini derivaadid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE200100209A (et) Tritsüklilised 3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20130428